Publications by authors named "E P Mamounas"
Purpose: NRG Oncology (NRG)/NSABP B-39/RTOG 0413 compared whole-breast irradiation (WBI) to accelerated partial-breast irradiation (APBI). APBI was not equivalent to WBI in local tumor control. Secondary outcome was Quality-of-life (QOL).
View Article and Find Full Text PDFPurpose: MammaPrint (MP) determines distant metastatic risk and may improve patient selection for extended endocrine therapy (EET). This study examined MP in predicting extended letrozole therapy (ELT) benefit in patients with early-stage breast cancer (BC) from the NSABP B-42 trial.
Patients And Methods: MP was tested in 1,866 patients randomly assigned to receive ELT or placebo.
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.
Mariana Chavez-MacGregor Jieling Miao Lajos Pusztai Matthew P Goetz Priya Rastogi Eleftherios P Mamounas
J Clin Oncol
September 2024
Article Synopsis
- The study investigated the effects of everolimus, an mTOR inhibitor, when used alongside endocrine therapy (ET) in high-risk, hormone receptor-positive metastatic breast cancer after chemotherapy, aiming to improve survival rates.
- In a phase III trial with 1,939 patients, results showed that adding everolimus to ET did not significantly enhance invasive disease-free survival (IDFS) or overall survival (OS) rates compared to a placebo, with hazard ratios indicating no substantial benefit.
- Subgroup analysis highlighted that premenopausal patients saw improved IDFS and OS with everolimus, whereas postmenopausal patients did not show significant differences, and treatment completion rates were lower in the everolimus group.
Article Synopsis
- The study examined the Breast Cancer Index (BCI) to predict benefits from extended endocrine therapy (EET) in hormone receptor-positive breast cancer patients participating in the NSABP B-42 trial.
- A total of 2,178 patients were analyzed, finding minimal overall RFI benefit from extended letrozole therapy, with no significant interaction between BCI levels and treatment outcome.
- However, after four years, patients with high BCI (H/I) showed significant benefits from EET, particularly in the HER2-negative subgroup, suggesting BCI's potential as a predictive marker for future studies.